$7.27
1.22% yesterday
Nasdaq, Feb 21, 10:00 pm CET
ISIN
US75901B1070
Symbol
RGNX

REGENXBIO, Inc. Stock price

$7.27
-0.30 3.96% 1M
-4.94 40.46% 6M
-0.46 5.95% YTD
-11.13 60.49% 1Y
-17.35 70.47% 3Y
-45.42 86.20% 5Y
-23.18 76.12% 10Y
Nasdaq, Closing price Fri, Feb 21 2025
-0.09 1.22%
ISIN
US75901B1070
Symbol
RGNX
Sector
Industry

Key metrics

Market capitalization $360.19m
Enterprise Value $250.54m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.97
P/S ratio (TTM) P/S ratio 4.27
P/B ratio (TTM) P/B ratio 1.19
Revenue growth (TTM) Revenue growth -15.14%
Revenue (TTM) Revenue $84.33m
EBIT (operating result TTM) EBIT $-243.78m
Free Cash Flow (TTM) Free Cash Flow $-184.74m
Cash position $255.46m
EPS (TTM) EPS $-5.03
P/E forward negative
P/S forward 4.14
EV/Sales forward 2.88
Short interest 16.91%
Show more

Is REGENXBIO, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,815 stocks worldwide.

REGENXBIO, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a REGENXBIO, Inc. forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a REGENXBIO, Inc. forecast:

Buy
91%
Hold
9%

Financial data from REGENXBIO, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
84 84
15% 15%
100%
- Direct Costs 55 55
2% 2%
65%
29 29
33% 33%
35%
- Selling and Administrative Expenses 59 59
11% 11%
70%
- Research and Development Expense 197 197
11% 11%
234%
-227 -227
7% 7%
-269%
- Depreciation and Amortization 17 17
3% 3%
20%
EBIT (Operating Income) EBIT -244 -244
7% 7%
-289%
Net Profit -239 -239
8% 8%
-283%

In millions USD.

Don't miss a Thing! We will send you all news about REGENXBIO, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

REGENXBIO, Inc. Stock News

Neutral
PRNewsWire
23 days ago
ROCKVILLE, Md. , Jan. 30, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced data from its RGX-121 (clemidsogene lanparvovec) program for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, will be shared at the 21st Annual WORLDSymposium™ 2025, taking place in San Diego, CA February 3-7, 2025.
Neutral
Seeking Alpha
about one month ago
Regenxbio's rolling BLA submission completion of RGX-121 for the treatment of patients with MPS II expected in Q1 of 2025. Partnership established with Nippon Shinyaku to develop RGX-121 and RGX-111 for the treatment of patients with MPS II and MPS I respectively. Data from both the ASCENT and ATMOSPHERE pivotal studies, using ABBV-RGX-314 for the treatment of patients with Wet Age-Related Macu...
Neutral
Seeking Alpha
about one month ago
Regenxbio Inc. remains undervalued despite its cutting-edge AAV gene therapy technology and promising assets like RGX-314 for wet AMD and RGX-121 for MPS II. RGX-314, partnered with AbbVie, targets wet AMD with global regulatory submissions expected in H1 2026; RGX-121 has a rolling BLA submission expected to complete in Q1 2025. Financially, RGNX has a market cap of $344mn and a cash balance o...
More REGENXBIO, Inc. News

Company Profile

REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Head office United States
CEO Curran Simpson
Employees 344
Founded 2008
Website www.regenxbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today